CJC-1295: DAC vs No DAC — Timing Strategies and Bloodwork Insights

CJC-1295 without DAC is essentially modified GRF 1-29, designed for a short pulsed release of growth hormone. The absence of DAC means it clears quickly, requiring more frequent administration to maintain elevated GH pulses.

The DAC version binds to serum albumin, extending its half-life from minutes to days. This creates a sustained elevation in GH and IGF-1 compared to the pulsed pattern of the no-DAC variant.

Research contexts differ: DAC creates a more constant signal, while no-DAC attempts to mimic natural pulsatility more closely. Neither approach is universally superior — the right choice depends on your protocol goals and observation window.

No-DAC variants typically require dosing 2-3 times daily to maintain serum concentrations. Morning fasted and pre-bed are common anchor points, with an optional third dose mid-day for those with flexible schedules.

DAC variants allow for simpler logistics: once-daily or every-other-day dosing is common. The extended half-life means one dose sustains elevated GH axis activity for an extended period.

Keep a dosing log that tracks not just quantity and frequency, but also timing relative to meals, sleep, and other variables. This context helps separate signal from noise in your observations.

Before starting either variant, establish baseline IGF-1, GH, and comprehensive metabolic panel. IGF-1 is the most practical marker for GH-axis activity over a multi-week window.

Mid-cycle bloodwork around week 4-6 lets you assess IGF-1 response relative to baseline. Large deviations from expected ranges may indicate dosing or timing needs adjustment.

Do not escalate doses rapidly hoping for faster results. GH axis saturation occurs, and higher doses often produce diminishing returns with increasing side effects like water retention and lethargy.

Avoid the temptation to combine multiple GH-releasing peptides and GHRH analogs simultaneously without clear documentation. Adding variables faster than you can track them reduces protocol interpretability.

If water retention becomes problematic, consider spacing doses further apart or reducing amount before abandoning the protocol entirely. Sometimes timing adjustments resolve tolerability issues while maintaining efficacy.